CIK 0001761612
- Non-accelerated filer
- Smaller reporting company
BICYCLE THERAPEUTICS PLC
Sign in to watch- Ticker
- BCYC
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- United Kingdom
- Entity type
- Operating
- Phone
- +44 1223261503
- Business address
- BLOCKS A & B, PORTWAY BUILDING, GRANTA PARK, GREAT ABINGTON, CAMBRIDGE, United Kingdom, CB21 6GS
- Former names
- BICYCLE THERAPEUTICS Ltd
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $64,039
- in 7 filings, $7K under 10b5-1 plans
Net −$64,039. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Lee Kevin −$27K CHIEF EXECUTIVE OFFICER sold 1% of stake
- Swanton Robert Charles −$12K Director sold 18% of stake
- Skynner Michael −$9K CHIEF SCIENTIFIC OFFICER sold 2% of stake
- Perry Jennifer Scott −$7K Chief Operating Officer sold 2% of stake
- Hannay Michael Charles Ferguson −$6K CHIEF PROD & SUPPLY CHAIN OFF sold 2% of stake
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-10-05 | Lee Kevin CHIEF EXECUTIVE OFFICER | Sale | −1,638 | $3.57 | $6K | 595,866 |
| 2026-10-02 | Lee Kevin CHIEF EXECUTIVE OFFICER | Sale | −6,167 | $3.47 | $21K | 597,504 |
| 2026-07-06 | Lee Kevin CHIEF EXECUTIVE OFFICER | Sale | −1,737 | $4.31 | $7K | 603,671 |
| 2026-07-02 | Lee Kevin CHIEF EXECUTIVE OFFICER | Sale | −5,905 | $4.27 | $25K | 605,408 |
| 2026-04-06 | Lee Kevin CHIEF EXECUTIVE OFFICER | Sale | −1,716 | $5.05 | $9K | 611,313 |
| 2026-04-02 | Lee Kevin CHIEF EXECUTIVE OFFICER | Sale | −5,967 | $4.91 | $29K | 613,029 |
| 2026-01-05 | Lee Kevin CHIEF EXECUTIVE OFFICER | Sale | −10,989 | $6.46 | $71K | 618,996 |
| 2026-01-02 | Lee Kevin CHIEF EXECUTIVE OFFICER | Grant or award | +165,000 | 640,310 | ||
| 2026-01-02 | Lee Kevin CHIEF EXECUTIVE OFFICER | Sale | −10,325 | $6.80 | $70K | 629,985 |
| 2026-01-02 | Lee Kevin CHIEF EXECUTIVE OFFICER | Grant or award · Employee Stock Option (right to buy) | +330,000 | 330,000 | ||
| 2025-10-03 | Lee Kevin CHIEF EXECUTIVE OFFICER | Sale | −3,231 | $8.41 | $27K | 475,310 |
| 2025-10-02 | Lee Kevin CHIEF EXECUTIVE OFFICER | Sale | −2,263 | $8.40 | $19K | 478,541 |
| 2025-07-03 | Lee Kevin CHIEF EXECUTIVE OFFICER | Sale | −3,193 | $7.44 | $24K | 480,804 |
| 2025-07-02 | Lee Kevin CHIEF EXECUTIVE OFFICER | Sale | −2,268 | $7.09 | $16K | 483,997 |
| 2025-04-03 | Lee Kevin CHIEF EXECUTIVE OFFICER | Sale | −3,432 | $7.48 | $26K | 486,265 |
| 2025-04-02 | Lee Kevin CHIEF EXECUTIVE OFFICER | Sale | −2,237 | $8.02 | $18K | 489,697 |
| 2025-01-03 | Lee Kevin CHIEF EXECUTIVE OFFICER | Sale | −3,092 | $14.75 | $46K | 491,934 |
| 2025-01-02 | Lee Kevin CHIEF EXECUTIVE OFFICER | Grant or award | +123,200 | 504,064 | ||
| 2025-01-02 | Lee Kevin CHIEF EXECUTIVE OFFICER | Sale | −9,038 | $14.09 | $127K | 495,026 |
| 2025-01-02 | Lee Kevin CHIEF EXECUTIVE OFFICER | Grant or award · Employee Stock Option (right to buy) | +308,000 | 308,000 |
Page 1 of 7 · 125 trades